ATE304792T1 - Regulierung der endogenen genexpression in zellen unter verwendung von zinkfingerproteinen - Google Patents

Regulierung der endogenen genexpression in zellen unter verwendung von zinkfingerproteinen

Info

Publication number
ATE304792T1
ATE304792T1 AT00906882T AT00906882T ATE304792T1 AT E304792 T1 ATE304792 T1 AT E304792T1 AT 00906882 T AT00906882 T AT 00906882T AT 00906882 T AT00906882 T AT 00906882T AT E304792 T1 ATE304792 T1 AT E304792T1
Authority
AT
Austria
Prior art keywords
zinc finger
endogene
regulation
cells
gene expression
Prior art date
Application number
AT00906882T
Other languages
English (en)
Inventor
George Norbert Cox Iii
Casey Christopher Case
Stephen P Eisenberg
Eric Edward Jarvis
Sharon Kaye Spratt
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Application granted granted Critical
Publication of ATE304792T1 publication Critical patent/ATE304792T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
AT00906882T 1999-01-12 2000-01-06 Regulierung der endogenen genexpression in zellen unter verwendung von zinkfingerproteinen ATE304792T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/229,037 US6534261B1 (en) 1999-01-12 1999-01-12 Regulation of endogenous gene expression in cells using zinc finger proteins
PCT/US2000/000409 WO2000041566A1 (en) 1999-01-12 2000-01-06 Regulation of endogenous gene expression in cells using zinc finger proteins

Publications (1)

Publication Number Publication Date
ATE304792T1 true ATE304792T1 (de) 2005-10-15

Family

ID=22859587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906882T ATE304792T1 (de) 1999-01-12 2000-01-06 Regulierung der endogenen genexpression in zellen unter verwendung von zinkfingerproteinen

Country Status (11)

Country Link
US (17) US6534261B1 (de)
EP (1) EP1061805B1 (de)
JP (3) JP2002534104A (de)
AT (1) ATE304792T1 (de)
AU (1) AU745844B2 (de)
CA (1) CA2323086C (de)
DE (2) DE60022705T8 (de)
DK (1) DK1061805T3 (de)
ES (1) ES2250103T3 (de)
GB (1) GB2348424B (de)
WO (1) WO2000041566A1 (de)

Families Citing this family (992)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262055B2 (en) * 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US7285416B2 (en) * 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
AU746454B2 (en) * 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
JP2002535995A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) * 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
GB9915126D0 (en) * 1999-06-30 1999-09-01 Imp College Innovations Ltd Control of gene expression
US7943731B1 (en) * 1999-08-11 2011-05-17 Massachusetts Institute Of Technology Dimerizing peptides
US6780590B2 (en) 1999-09-14 2004-08-24 Sangamo Biosciences, Inc. Gene identification
US7329728B1 (en) * 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
HK1049515B (en) * 1999-12-06 2006-01-13 Sangamo Biosciences Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7151201B2 (en) * 2000-01-21 2006-12-19 The Scripps Research Institute Methods and compositions to modulate expression in plants
AU2964101A (en) * 2000-01-21 2001-07-31 Scripps Research Institute, The Methods and compositions to modulate expression in plants
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
WO2001053478A2 (en) * 2000-01-24 2001-07-26 Gendaq Limited Methods for regulating transcription in plants by introduction of engireed zinc finger polypeptides
DE60143192D1 (de) * 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
EP1276860B1 (de) 2000-04-28 2007-09-26 Sangamo Biosciences Inc. Datenbanken von regulatorischen sequenzen, methoden zu ihrer herstellung und verwendung
US20030049649A1 (en) * 2000-04-28 2003-03-13 Wolffe Alan P. Targeted modification of chromatin structure
ATE353361T1 (de) * 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
CA2407695C (en) * 2000-04-28 2015-03-31 Sangamo Biosciences, Inc. Methods for binding an exogenous molecule to cellular chromatin
WO2001084148A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
WO2001083819A2 (en) * 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
US20040039175A1 (en) * 2000-05-08 2004-02-26 Yen Choo Modulation of viral gene expression by engineered zinc finger proteins
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
US6492117B1 (en) * 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US20030082561A1 (en) * 2000-07-21 2003-05-01 Takashi Sera Zinc finger domain recognition code and uses thereof
EP1303608A2 (de) * 2000-07-21 2003-04-23 Syngenta Participations AG Code zur erkennung von zinkfingerdomänen und dessen verwendungen
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2002026960A2 (en) * 2000-09-29 2002-04-04 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
WO2002031166A2 (en) * 2000-10-13 2002-04-18 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use
AU2002241532A1 (en) * 2000-11-30 2002-06-11 Sangamo Biosciences, Inc. Human heparanase gene regulatory sequences
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
AU2002225187A1 (en) * 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
CA2435394C (en) 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
WO2002060477A1 (en) * 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
GB0106786D0 (en) * 2001-03-19 2001-05-09 Gendaq Ltd Gene regulation
US8735153B2 (en) 2001-09-24 2014-05-27 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US20040259258A1 (en) * 2001-12-07 2004-12-23 Kim Jin-Soo Regulation of prokaryotic gene expression with zinc finger proteins
EP1451297A4 (de) * 2001-12-07 2006-06-28 Toolgen Inc Phänotyp-screening chimärer proteine
AU2002367173A1 (en) * 2001-12-21 2003-07-15 Achillion Pharmaceuticals, Inc. Antifungal compositions
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
AU2003251286B2 (en) * 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
MXPA05001829A (es) * 2002-08-12 2005-05-27 Monsanto Technology Llc Metodos para aumentar el contenido de aceite de las plantas.
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
JP2006502748A (ja) * 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
US20070178454A1 (en) * 2002-10-21 2007-08-02 Joung J K Context sensitive paralell optimization of zinc finger dna binding domains
US20060246440A1 (en) * 2002-10-23 2006-11-02 Joung J K Methods for producing zinc finger proteins that bind to extended dna target sequences
EP1579005A4 (de) * 2002-11-15 2007-07-25 Sangamo Biosciences Inc Verfahren und zusammensetzungen zur analyse regulatorischer sequenzen
US20060251643A1 (en) * 2002-12-09 2006-11-09 Toolgen, Inc. Regulatory zinc finger proteins
US8071285B1 (en) * 2003-05-14 2011-12-06 Carl Henry Lawyer Zinc finger protein derivatives and methods of using same
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
CA2542232A1 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
WO2004108883A2 (en) * 2003-06-10 2004-12-16 Toolgen, Inc. Transducible dna-binding proteins
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
JP4555292B2 (ja) 2003-08-08 2010-09-29 サンガモ バイオサイエンシズ インコーポレイテッド 標的化された切断及び組換えの方法及び組成物
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US7407776B2 (en) 2003-09-19 2008-08-05 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1737498A2 (de) * 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Zink-finger-proteine zur behandlung von neuropathischen schmerzen
EP1732945B1 (de) * 2004-04-08 2014-12-24 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur modulation der kardialen kontraktivität
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
US20060035251A1 (en) * 2004-06-30 2006-02-16 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
EP2292274A1 (de) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Zusammensetzungen und Methoden zur Protein Herstellung
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
EP1869075B1 (de) * 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Antiangiogene methoden und zusammensetzungen
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
WO2007002563A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
WO2007014275A2 (en) * 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
WO2007106603A2 (en) * 2006-01-06 2007-09-20 The Scripps Research Institute Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
ATE476986T1 (de) 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
US20090305977A1 (en) * 2006-02-09 2009-12-10 Sangamo Bioscience, Inc. Method for treating peripheral arterial disease with zinc finger proteins
GB0607063D0 (en) * 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
WO2007136685A2 (en) * 2006-05-19 2007-11-29 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
ES2465996T3 (es) 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
US8148129B2 (en) * 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
US7739870B2 (en) * 2006-08-04 2010-06-22 Briggs And Stratton Corporation Hydrostatic transmission
KR101439568B1 (ko) 2006-08-11 2014-09-12 다우 아그로사이언시즈 엘엘씨 아연 손가락 뉴클레아제-매개 상동 재조합
WO2008060510A2 (en) * 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
ES2586210T3 (es) 2006-12-14 2016-10-13 Sangamo Biosciences, Inc. Proteínas de dedo de zinc no canónicas optimizadas
CA2684378C (en) 2007-04-26 2016-11-29 Sangamo Biosciences, Inc. Targeted integration into the ppp1r12c locus
US7919313B2 (en) * 2007-07-12 2011-04-05 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
US8105827B2 (en) * 2007-09-06 2012-01-31 Academia Sinica Protein expression systems
EP2188384B1 (de) * 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Schnelle in-vivo-identifizierung von biologisch aktiven nukleasen
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8399218B2 (en) 2007-09-27 2013-03-19 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
PT2222839E (pt) 2007-12-03 2015-11-30 Sanbio Inc Métodos e composições para modular a diferenciação de células pluripotentes
WO2009079399A2 (en) * 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
AU2009212247A1 (en) * 2008-02-08 2009-08-13 Sangamo Therapeutics, Inc. Treatment of chronic pain with zinc finger proteins
JP2011518555A (ja) 2008-04-14 2011-06-30 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的組込みのための線形ドナーコンストラクト
WO2009146179A1 (en) * 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
MX2010011511A (es) 2008-04-21 2011-06-09 Danziger Innovations Ltd Vectores de expresion viral de planta y uso de los mismos para generar variaciones genotipicas en genomas de plantas.
PL2274430T3 (pl) 2008-04-30 2017-09-29 Sanbio Inc Komórki regenerujące nerwy ze zmianami w metylacji DNA
CA2725773C (en) * 2008-05-28 2017-12-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
EP2294191B1 (de) 2008-06-10 2016-09-28 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur erzeugung von bax- und bak-mangel-zelllinien
CN102159197A (zh) 2008-07-18 2011-08-17 希尔氏宠物营养品公司 治疗骨关节炎的组合物和方法
WO2010019526A1 (en) * 2008-08-14 2010-02-18 Brent Lee Dynamic filtration device using centrifugal force
AU2009283194B2 (en) 2008-08-22 2014-10-16 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
CN102264915B (zh) 2008-10-29 2014-04-16 桑格摩生物科学股份有限公司 失活谷氨酰胺合成酶基因表达的方法和组合物
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023159A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Ovine genome editing with zinc finger nucleases
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023157A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Equine genome editing with zinc finger nucleases
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110016542A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Canine genome editing with zinc finger nucleases
AU2009322964B2 (en) 2008-12-04 2014-10-09 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
AR074783A1 (es) 2008-12-17 2011-02-09 Dow Agrosciences Llc Metodos y composiciones para expresar uno o mas productos de un acido nucleico exogeno integrado al locus zp15 de una celula vegetal
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US12612435B2 (en) 2009-01-12 2026-04-28 Ulla Bonas Modular DNA-binding domains and methods of use
EP2206723A1 (de) 2009-01-12 2010-07-14 Bonas, Ulla Modulare DNA-bindende Domänen
AU2010211057B2 (en) * 2009-02-04 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathies
EP2393923A4 (de) * 2009-02-06 2012-11-14 Gilead Biologics Inc Verfahren und zusammensetzungen zur behandlung von neovaskularisierung
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
CA2756833C (en) * 2009-04-09 2019-11-19 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2011005849A1 (en) 2009-07-08 2011-01-13 Cellular Dynamics International, Inc. Modified ips cells having a mutant form of human immunodeficiency virus (hiv) cellular entry gene
CA2769262C (en) * 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
ES2550202T3 (es) * 2009-08-03 2015-11-05 Recombinetics, Inc. Métodos y composiciones para la modificación dirigida de genes
EP3156504B1 (de) * 2009-08-11 2018-10-31 Sangamo Therapeutics, Inc. Für gezielte modifikation homozygote organismen
CN102713601A (zh) * 2009-08-21 2012-10-03 吉联亚生物科技有限公司 体外筛选试验
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
KR20120054077A (ko) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
EP2467162A4 (de) * 2009-08-21 2013-10-02 Gilead Biologics Inc Therapeutische verfahren und zusammensetzungen
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
AU2015203725B2 (en) * 2009-10-22 2017-02-02 Corteva Agriscience Llc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
KR101813981B1 (ko) * 2009-10-22 2018-01-04 다우 아그로사이언시즈 엘엘씨 지방산 생합성에 포함된 식물 유전자를 표적하는 조작된 징크 핑거 단백질
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
NO2510096T3 (de) 2009-12-10 2015-03-21
US8704041B2 (en) * 2009-12-30 2014-04-22 Pioneer Hi Bred International Inc Methods and compositions for targeted polynucleotide modification
US20110165649A1 (en) * 2010-01-06 2011-07-07 Brett Tyler Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
US20110203012A1 (en) * 2010-01-21 2011-08-18 Dotson Stanton B Methods and compositions for use of directed recombination in plant breeding
JP5902631B2 (ja) * 2010-01-22 2016-04-13 ダウ アグロサイエンシィズ エルエルシー 標的化ゲノム変更
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2011097036A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
WO2011117249A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
US9315825B2 (en) * 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CN107805278A (zh) * 2010-04-13 2018-03-16 西格马-奥尔德里奇有限责任公司 产生内源标记的蛋白的方法
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
PL2566972T3 (pl) 2010-05-03 2020-06-29 Sangamo Therapeutics, Inc. Kompozycje do wiązania modułów z motywem palca cynkowego
EP3156062A1 (de) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Neuartige dna-bindende proteine und verwendungen davon
EP2576800B1 (de) 2010-05-28 2019-01-30 Corbion Biotech, Inc. Verfahren zur Herstellung von Ölen aus Prototheca
CA3157027A1 (en) 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
BR112013001685B1 (pt) 2010-07-23 2021-10-13 Sigma-Aldrich Co. Llc Método para editar pelo menos uma sequência cromossômica endógena em uma célula pela inserção de uma sequência na sequência cromossômica
EP3511420B1 (de) 2010-09-27 2021-04-07 Sangamo Therapeutics, Inc. Zusammensetzungen zur hemmung des eindringens von viren in zellen
KR101930711B1 (ko) 2010-10-12 2018-12-19 더 칠드런스 호스피탈 오브 필라델피아 혈우병 ｂ의 치료를 위한 방법 및 조성물
AU2011323288B2 (en) 2010-11-03 2016-05-26 Corbion Biotech, Inc. Microbial oils with lowered pour points, dielectric fluids produced therefrom, and related methods
CA2821547A1 (en) 2010-12-29 2012-07-05 Sigma-Aldrich Co. Llc Cells having disrupted expression of proteins involved in adme and toxicology processes
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
AR084844A1 (es) 2011-01-14 2013-06-26 Jones Jeffrey B Arboles de citricos con resistencia a cancro de los citricos
AU2012212079B2 (en) 2011-02-02 2016-07-28 Corbion Biotech, Inc. Tailored oils produced from recombinant oleaginous microorganisms
WO2012139045A1 (en) 2011-04-08 2012-10-11 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
ES2671733T3 (es) 2011-06-30 2018-06-08 Sigma Aldrich Co. Llc Células deficientes en ácido CMP-N-acetilneuramínico hidroxilasa y/o glucoproteína alfa-1,3-galactosil transferasa
US20130097734A1 (en) 2011-07-12 2013-04-18 Two Blades Foundation Late blight resistance genes
US20140274812A1 (en) 2011-07-15 2014-09-18 The General Hospital Corporation Methods of Transcription Activator Like Effector Assembly
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US9150847B2 (en) 2011-09-21 2015-10-06 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
CN103958668A (zh) 2011-09-23 2014-07-30 路易斯维尔大学研究基金会公司 用于扩充细胞及改善嫁接的方法和组合物
MA36970A1 (fr) * 2011-10-11 2016-03-31 Aliophtha Ag Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
HK1200871A1 (en) 2011-11-16 2015-08-14 Sangamo Therapeutics, Inc. Modified dna-binding proteins and uses thereof
BR112014016614B1 (pt) 2012-01-11 2022-02-01 Sigma-Aldrich Co. Llc Métodos para produzir uma célula deficiente em manosil (alfa-1,3-)-glicoproteína beta-1,2- nacetilglucosa-miniltransferase i (mgat1) e produzir uma proteína recombinante apresentando um ou mais resíduos de manose terminal
BR112014018294B1 (pt) 2012-01-26 2022-01-11 Norfolk Plant Sciences, Ltd Método para produzir uma planta, cassete de expressão, e, célula bacteriana
EP4218727A3 (de) 2012-01-27 2023-08-30 SanBio, Inc. Verfahren und zusammensetzungen zur modulation der angiogenese und vaskulogenese
JP6309461B2 (ja) 2012-02-28 2018-04-11 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ ヒストンアセチル化の標的化
NZ629427A (en) * 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
EP2839018B1 (de) 2012-04-18 2019-06-05 Corbion Biotech, Inc. Massgeschneiderte öle
WO2013158309A2 (en) 2012-04-18 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Non-disruptive gene targeting
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
JP6352250B2 (ja) 2012-05-02 2018-07-04 ダウ アグロサイエンシィズ エルエルシー リンゴ酸デヒドロゲナーゼの標的改変
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
US11120889B2 (en) 2012-05-09 2021-09-14 Georgia Tech Research Corporation Method for synthesizing a nuclease with reduced off-site cleavage
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
CA2875945A1 (en) 2012-06-07 2013-12-12 The Children's Hospital Of Philadelphia Controlled gene expression methods
MX2014015204A (es) 2012-06-12 2015-08-07 Genentech Inc Metodos y composiciones para generar alelos con inactivacion condicional.
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
EP2872154B1 (de) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
CA2875618C (en) 2012-07-11 2021-04-27 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
JP2015527889A (ja) * 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
DK2890780T3 (da) * 2012-08-29 2020-09-21 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
KR102201867B1 (ko) 2012-09-04 2021-01-12 더 스크립스 리서치 인스티튜트 표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들
HK1217732A1 (zh) 2012-09-07 2017-01-20 美国陶氏益农公司 Fad3性能基因座及相應的能夠誘導靶向斷裂的靶位點特異性結合蛋白
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
EP3257952B1 (de) 2012-09-11 2020-02-12 Life Technologies Corporation Nukleinsäureamplifikation
WO2014043143A1 (en) 2012-09-11 2014-03-20 Life Technologies Corporation Nucleic acid amplification
EP3763810A3 (de) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T-zell-modifizierende verbindungen und verwendungen davon
EP2906602B1 (de) 2012-10-12 2019-01-16 The General Hospital Corporation Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
MX367031B (es) 2012-11-01 2019-08-02 Cellectis Plantas para la produccion de proteinas terapeuticas.
US9279816B2 (en) 2012-11-15 2016-03-08 Board Of Trustees Of The University Of Arkansas Methods and kits for isolation and analysis of a chromatin region
US9506915B2 (en) 2012-11-15 2016-11-29 Board Of Trustees Of The University Of Arkansas Methods and kits for isolation and analysis of a chromatin region
AU2013344375B2 (en) 2012-11-16 2017-09-14 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
IL239317B (en) 2012-12-12 2022-07-01 Broad Inst Inc Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
CN114634950A (zh) 2012-12-12 2022-06-17 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP2931898B1 (de) 2012-12-12 2016-03-09 The Broad Institute, Inc. Technische konzeption und optimierung von systemen, verfahren und zusammensetzungen zur sequenzmanipulation funktionellen domänen
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
JP2016504026A (ja) 2012-12-12 2016-02-12 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための系、方法および最適化ガイド組成物のエンジニアリング
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP2896697B1 (de) 2012-12-12 2015-09-02 The Broad Institute, Inc. Herstellung von Systemen, Verfahren und optimierten Führungszusammensetzungen zur Sequenzmanipulation
US20140173783A1 (en) 2012-12-13 2014-06-19 Dow Agrosciences Llc Precision gene targeting to a particular locus in maize
SG10201912991WA (en) 2012-12-17 2020-03-30 Harvard College Rna-guided human genome engineering
PL2934097T3 (pl) 2012-12-21 2018-11-30 Cellectis Ziemniaki o ograniczonej słodkości indukowanej chłodem
EP3919505B1 (de) 2013-01-16 2023-08-30 Emory University Verwendungen von cas9-nukleinsäurekomplexen
CA2900338C (en) 2013-02-07 2024-11-05 The General Hospital Corporation TRANSCRIPTIONAL ACTIVATORS TALE
EP2958996B1 (de) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur verbesserung einer nuklease-vermittelten genunterbrechung
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US10378027B2 (en) * 2013-03-15 2019-08-13 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP2975942B1 (de) 2013-03-21 2018-08-08 Sangamo Therapeutics, Inc. Gezielte disruption von t-zell rezeptorgenen mit manipulierten zinkfinger-proteinnukleasen
RU2723130C2 (ru) 2013-04-05 2020-06-08 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы и композиции для встраивания экзогенной последовательности в геном растений
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
EP3730615A3 (de) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
JP2016521561A (ja) * 2013-06-14 2016-07-25 セレクティス 植物における非トランスジェニックのゲノム編集のための方法
EP3725885A1 (de) 2013-06-17 2020-10-21 The Broad Institute, Inc. Funktionale genomik unter verwendung von crispr-cas-systemen, zusammensetzungen, verfahren, schirme und anwendungen davon
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
JP6738729B2 (ja) 2013-06-17 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
CN105793425B (zh) 2013-06-17 2021-10-26 布罗德研究所有限公司 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CA2920899C (en) 2013-08-28 2023-02-28 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
CA2922428A1 (en) 2013-08-29 2015-03-05 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for rna-guided treatment of hiv infection
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
CN105829521A (zh) 2013-10-04 2016-08-03 索拉兹米公司 定制油
CN110713995B (zh) 2013-10-17 2023-08-01 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
BR102014027442B1 (pt) 2013-11-04 2022-09-27 Dow Agrosciences Llc Molécula de ácido nucleico recombinante, uso de uma planta de milho, parte de planta de milho ou célula de planta de milho compreendendo a mesma e método para produzir uma célula vegetal transgênica compreendendo um dna de interesse
KR102269769B1 (ko) 2013-11-04 2021-06-28 코르테바 애그리사이언스 엘엘씨 최적 메이즈 유전자좌
UY35814A (es) 2013-11-04 2015-05-29 Dow Agrosciences Llc ?lugares óptimos para la soja?.
MX358066B (es) 2013-11-04 2018-08-03 Dow Agrosciences Llc Óptimos loci de soya.
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
AU2014346424B2 (en) 2013-11-11 2020-09-17 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
HUE056436T2 (hu) 2013-11-13 2022-02-28 Childrens Medical Center Nukleáz közvetítette génexpresszió-szabályozás
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
ES2813367T3 (es) 2013-12-09 2021-03-23 Sangamo Therapeutics Inc Métodos y composiciones para ingeniería genómica
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
RU2016128077A (ru) 2013-12-12 2018-12-06 Те Брод Инститьют Инк. Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
BR112016013213A2 (pt) 2013-12-12 2017-12-05 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
US20170166920A1 (en) 2014-01-30 2017-06-15 Two Blades Foundation Plants with enhanced resistance to phytophthora
HUE051232T2 (hu) 2014-02-03 2021-03-01 Sangamo Therapeutics Inc Béta-talasszémia kezelésére szolgáló eljárások és készítmények
AU2015218576B2 (en) 2014-02-24 2020-02-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
BR112016020287B1 (pt) 2014-03-04 2022-06-28 Sigma-Aldrich Co. Llc Uso de uma linhagem celular de ovário de hamster chinês (cho) geneticamente modificada, composição e métodos para reduzir o risco de contaminação viral de um sistema de produção biológico e para reduzir ou prevenir a contaminação viral de um produto de proteína recombinante
ES2974625T3 (es) 2014-03-14 2024-06-28 Cibus Us Llc Procedimientos y composiciones para aumentar la eficacia de la modificación génica dirigida mediante reparación génica mediada por oligonucleótidos
JP6594891B2 (ja) 2014-03-18 2019-10-23 サンガモ セラピューティクス， インコーポレイテッド ジンクフィンガータンパク質発現を調節するための方法および組成物
MX392639B (es) 2014-03-21 2025-03-24 Univ Leland Stanford Junior Vectores virales recombinantes para la integración de transgenes
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
CA2946385A1 (en) 2014-04-22 2015-10-29 Q-State Biosciences, Inc. Diagnostic methods for neuronal disorders
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
CN106413760B (zh) 2014-05-08 2020-01-14 桑格摩生物科学股份有限公司 用于治疗亨廷顿病的方法和组合物
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3139909B1 (de) 2014-05-09 2025-01-01 Yale University Mit hyperverzweigtem polyglycerin beschichtete partikeln
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
KR20170005494A (ko) 2014-05-30 2017-01-13 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 잠복 바이러스 감염에 대한 치료제를 전달하는 조성물 및 방법
EP3151846A4 (de) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur nukleasekonstruktion
EP3674408A1 (de) 2014-06-16 2020-07-01 The Johns Hopkins University Zusammensetzungen und verfahren zur expression von crispr-führungs-rnas mithilfe des h1-promotors
CA2952906A1 (en) 2014-06-20 2015-12-23 Cellectis Potatoes with reduced granule-bound starch synthase
EP3919621A1 (de) 2014-06-23 2021-12-08 The General Hospital Corporation Genomweite unbeeinflusste, durch sequenzierung (guide-seq) beurteilte identifizierung von dsbs
EP3166964A1 (de) 2014-07-08 2017-05-17 Vib Vzw Mittel und verfahren zur steigerung des pflanzenertrags
EP3167053B1 (de) 2014-07-10 2019-10-09 Corbion Biotech, Inc. Neuartige ketoacyl-acp-synthasegene und verwendungen davon
FI3169778T3 (fi) 2014-07-14 2023-12-13 Univ Washington State Ituradan soluja ablatoiva nanos-geeninpoisto
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9757420B2 (en) 2014-07-25 2017-09-12 Sangamo Therapeutics, Inc. Gene editing for HIV gene therapy
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
WO2016018664A2 (en) * 2014-07-30 2016-02-04 Texas Tech University System Conditional cytotoxic gene therapy vector for selectable stem cell modification for anti hiv gene therapy
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN107429241B (zh) 2014-08-14 2025-10-24 百奥赛图(北京)医药科技股份有限公司 Dna敲入系统
DK3180426T3 (da) 2014-08-17 2020-03-30 Broad Inst Inc Genomredigering ved anvendelse af cas9-nickaser
HUE055583T2 (hu) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
AU2015320694B2 (en) 2014-09-24 2021-11-11 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
IL287561B2 (en) 2014-10-01 2024-03-01 Massachusetts Gen Hospital Methods for increasing efficiency of nuclease-induced homology-directed repair
GB201418965D0 (de) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3230451B1 (de) 2014-12-12 2021-04-07 The Broad Institute, Inc. Geschützte guide-rnas (pgrnas)
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
HK1246690A1 (zh) 2015-01-21 2018-09-14 Sangamo Therapeutics, Inc. 用於鉴定高度特异性核酸酶的方法和组合物
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
US10048275B2 (en) 2015-03-13 2018-08-14 Q-State Biosciences, Inc. Cardiotoxicity screening methods
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
EP3283633A2 (de) 2015-04-15 2018-02-21 Dow AgroSciences LLC Pflanzenpromoter zur transgenen expression
BR112017021703B1 (pt) 2015-04-15 2023-11-28 Corteva Agriscience Llc Promotor de planta para expressão de transgene
US20190275168A1 (en) 2015-04-30 2019-09-12 The Trustees Of Columbia University In The City Of New York Gene therapy for autosomal dominant diseases
CN108026566A (zh) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
EP3294892B1 (de) 2015-05-09 2020-11-25 Two Blades Foundation Kraut- und knollenfäule-resistenzgen aus solanum americanum und verfahren zur verwendung
JP6873917B2 (ja) 2015-05-12 2021-05-19 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ介在性遺伝子発現調節
CN107614680A (zh) * 2015-05-14 2018-01-19 南加利福尼亚大学 利用重组核酸内切酶系统的最佳化基因编辑
WO2016187543A1 (en) 2015-05-21 2016-11-24 Q-State Biosciences, Inc. Optogenetics microscope
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
CA3000155A1 (en) 2015-05-29 2016-12-08 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
EP3302525A2 (de) 2015-06-05 2018-04-11 Novartis AG Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
ES2886599T3 (es) 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
EP3436575A1 (de) 2015-06-18 2019-02-06 The Broad Institute Inc. Neuartige crispr-enzyme und -systeme
AU2016279077A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN108024544B (zh) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
RU2018107842A (ru) 2015-08-06 2019-09-09 Дзе Кьюрейторз Оф Дзе Юниверсити Оф Миссури Устойчивые к патогенам животные, имеющие модифицированные гены cd163
US11214800B2 (en) 2015-08-18 2022-01-04 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017040709A1 (en) 2015-08-31 2017-03-09 Caribou Biosciences, Inc. Directed nucleic acid repair
CN108350453A (zh) 2015-09-11 2018-07-31 通用医疗公司 核酸酶dsb的完全查询和测序(find-seq)
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
TW201718861A (zh) 2015-09-22 2017-06-01 道禮責任有限公司 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
TW201718862A (zh) 2015-09-22 2017-06-01 Dow Agrosciences Llc 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
LT3352776T (lt) 2015-09-23 2025-07-10 Sangamo Therapeutics, Inc. Htt represoriai ir jų panaudojimas
JP2018529353A (ja) 2015-09-30 2018-10-11 ザ ジェネラル ホスピタル コーポレイション 配列決定法による切断事象の包括的生体外報告（ＣＩＲＣＬＥ−ｓｅｑ）
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
EP4089175A1 (de) 2015-10-13 2022-11-16 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
CN108473997B (zh) 2015-10-22 2022-04-12 美国陶氏益农公司 用于转基因表达的植物启动子
CN109153980B (zh) 2015-10-22 2023-04-14 布罗德研究所有限公司 Vi-b型crispr酶和系统
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
CN115141836B (zh) 2015-10-28 2024-08-27 桑格摩生物治疗股份有限公司 肝特异性构建体、因子viii表达盒及其使用方法
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
US20170121726A1 (en) 2015-11-04 2017-05-04 Dow Agrosciences Llc Plant promoter for transgene expression
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
WO2017095967A2 (en) 2015-11-30 2017-06-08 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
AU2016374253B2 (en) 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
ES2983043T3 (es) 2015-12-18 2024-10-21 Sangamo Therapeutics Inc Alteración dirigida del receptor de células T
MX2018008345A (es) 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia.
IL304088A (en) 2016-01-11 2023-08-01 Univ Leland Stanford Junior Systems containing chimeric proteins and their uses for controlling gene expression
AU2017207818B2 (en) 2016-01-15 2024-03-28 Regents Of The University Of Minnesota Methods and compositions for the treatment of neurologic disease
EP4646936A3 (de) 2016-02-02 2025-11-19 Cellectis Modifizierung der sojaölzusammensetzung durch gezieltes knockout der fad3a/b/c-gene
CN109069568B (zh) 2016-02-02 2023-07-07 桑格摩生物治疗股份有限公司 用于连接dna结合结构域和切割结构域的组合物
KR102841205B1 (ko) 2016-02-09 2025-08-01 시버스 유에스 엘엘씨 올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
US11674952B2 (en) 2016-02-24 2023-06-13 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
WO2023150553A1 (en) 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
AU2017238512B2 (en) 2016-03-23 2022-12-08 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3443081A4 (de) 2016-04-13 2019-10-30 Duke University Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
SG11201810179RA (en) 2016-04-19 2018-12-28 Broad Inst Inc Novel crispr enzymes and systems
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
US11410746B2 (en) 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
EP3464323B1 (de) 2016-05-27 2021-09-22 Aadigen, LLC Peptide und nanopartikel zur intrazellulären abgabe von genombearbeitungsmolekülen
LT3604527T (lt) 2016-06-02 2021-06-25 Sigma-Aldrich Co., Llc Programuojamų, dnr surišančių baltymų panaudojimas tiksliniam genomo modifikavimui pagerinti
CN109790551A (zh) 2016-06-16 2019-05-21 奥斯陆大学医院Hf 改进的基因编辑
US11788083B2 (en) 2016-06-17 2023-10-17 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
WO2018005445A1 (en) 2016-06-27 2018-01-04 The Broad Institute, Inc. Compositions and methods for detecting and treating diabetes
EP3475706B1 (de) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US12595478B2 (en) 2016-06-29 2026-04-07 The Broad Institute, Inc. Crispr-Cas systems having destabilization domain
EP3484870B1 (de) 2016-07-13 2022-11-16 Vertex Pharmaceuticals Incorporated Verfahren, zusammensetzungen und kits zur erhöhung der genomeditierungseffizienz
EP3485023B1 (de) 2016-07-15 2023-11-15 Salk Institute for Biological Studies Verfahren und zusammensetzungen zum genom-editieren von sich nichtteilenden zellen
EP4275747A3 (de) 2016-07-19 2024-01-24 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung
KR20190031306A (ko) 2016-07-21 2019-03-25 맥스시티 인코포레이티드 게놈 dna를 변경하기 위한 방법 및 조성물
EP3490556A4 (de) 2016-07-27 2020-04-15 Case Western Reserve University Verbindungen und verfahren zur förderung der myelinisierung
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
JP7134944B2 (ja) 2016-08-11 2022-09-12 ザ ジャクソン ラボラトリー 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
BR112019003100A2 (pt) 2016-08-24 2019-07-09 Sangamo Therapeutics, Inc. regulação da expressão gênica usando nucleases manipuladas
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
IL300783B2 (en) 2016-08-24 2026-03-01 Sangamo Therapeutics Inc Engineered nucleases with target-specific zinc fingers
WO2018049009A2 (en) 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
WO2018067265A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
US10400246B2 (en) 2016-10-03 2019-09-03 Dow Agrosciences Llc Plant promoter for transgene expression
EP3519433A1 (de) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-spezifische bindungsmoleküle
EP3523422B1 (de) 2016-10-05 2024-12-25 FUJIFILM Cellular Dynamics, Inc. Erzeugung reifer linien aus induzierten pluripotenten stammzellen mit mecp2-unterbrechung
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
EP3525832A4 (de) 2016-10-14 2020-04-29 The General Hospital Corp. Epigenetisch regulierte stellenspezifische nukleasen
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
CN110022904B (zh) 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
US11766400B2 (en) 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
US11020492B2 (en) 2016-10-31 2021-06-01 Sangamo Therapeutics, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
CA3042259A1 (en) 2016-11-04 2018-05-11 Flagship Pioneering Innovations V. Inc. Novel plant cells, plants, and seeds
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
US11312972B2 (en) 2016-11-16 2022-04-26 Cellectis Methods for altering amino acid content in plants through frameshift mutations
EP3548616A4 (de) 2016-12-01 2020-05-13 Sangamo Therapeutics, Inc. Tau-modulatoren und verfahren und zusammensetzungen zur abgabe davon
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
CA3046199A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
EP3555299A1 (de) 2016-12-16 2019-10-23 Two Blades Foundation Kraut- und knollenfäuleresistenzgene und verfahren zur verwendung
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
EP3559230B1 (de) 2016-12-20 2023-09-06 Bristol-Myers Squibb Company Verfahren zur verbesserung der effizienz von homologie-gerichteter reparatur (hdr) im zellulären genom
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11597947B2 (en) 2016-12-29 2023-03-07 Asc Therapeutics Inc. Gene editing method using virus
US20190390241A1 (en) 2017-01-24 2019-12-26 Sigma-Aldrich Co. Llc Viral resistant cells and culture systems
SG11201906795SA (en) 2017-01-28 2019-08-27 Inari Agriculture Inc Novel plant cells, plants, and seeds
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CN119351474A (zh) 2017-02-22 2025-01-24 克里斯珀医疗股份公司 用于基因编辑的组合物和方法
EP3592381A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Krebsimpfstoff
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018175581A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018175924A1 (en) 2017-03-24 2018-09-27 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EA201992358A1 (ru) 2017-04-03 2020-03-24 Инкоудид Терапьютикс, Инк. Тканеселективная экспрессия трансгена
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
WO2018191558A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
EP3610009A1 (de) 2017-04-12 2020-02-19 The Broad Institute, Inc. Neuartige typ-vi-crispr-orthologe und systeme
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
KR20190140950A (ko) 2017-04-20 2019-12-20 오레곤 헬스 앤드 사이언스 유니버시티 인간 유전자 교정
EP3612023A4 (de) 2017-04-20 2021-05-12 Egenesis, Inc. Verfahren zur erzeugung genetisch modifizierter tiere
US12208140B2 (en) 2017-04-21 2025-01-28 The Broad Institute, Inc. Targeted delivery to beta cells
ES2977620T3 (es) 2017-04-25 2024-08-27 Cellectis Alfalfa con composición reducida de lignina
ES2981611T3 (es) 2017-04-28 2024-10-09 Univ Colorado Regents Métodos para tratar la artritis reumatoide mediante el uso de la edición del genoma guiada por ARN del gen de HLA
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
RU2019140867A (ru) 2017-05-12 2021-06-15 Зе Джексон Лаборатори Nsg мыши, не имеющие mhc класса i и класса ii
WO2018209209A1 (en) 2017-05-12 2018-11-15 Two Blades Foundation Methods for screening proteins for pattern recognition receptor function in plant protoplasts
US12297436B2 (en) 2017-05-18 2025-05-13 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
AU2018273986A1 (en) 2017-05-25 2019-12-12 The General Hospital Corporation Bipartite base editor (BBE) architectures and type-II-C-Cas9 zinc finger editing
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
SG11201912179SA (en) 2017-06-15 2020-01-30 Univ California Targeted non-viral dna insertions
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CA3064601A1 (en) 2017-06-26 2019-01-03 President And Fellows Of Harvard College Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
CN111278276B (zh) 2017-06-28 2023-05-26 美国陶氏益农公司 用于转基因表达的植物启动子
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
BR112020001059A2 (pt) 2017-07-18 2020-07-14 Calimmune, Inc. composições e métodos para o tratamento de beta-hemoglobinopatias
US11261458B2 (en) 2017-07-28 2022-03-01 Two Blades Foundation Potyvirus resistance genes and methods of use
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CA3071683A1 (en) 2017-08-08 2019-02-14 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
CN111263810A (zh) 2017-08-22 2020-06-09 纳匹基因公司 使用多核苷酸指导的核酸内切酶的细胞器基因组修饰
EP3676376B1 (de) 2017-08-30 2025-01-15 President and Fellows of Harvard College Hocheffiziente baseneditoren mit gam
JP7816916B2 (ja) 2017-09-08 2026-02-18 キージーン ナムローゼ フェンノートシャップ バランスがとれたインデル
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
EP3692063A1 (de) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-spezifische bindungsmoleküle
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11629342B2 (en) 2017-10-17 2023-04-18 President And Fellows Of Harvard College Cas9-based transcription modulation systems
IT201700120699A1 (it) 2017-10-24 2019-04-24 Humanitas Mirasole Spa Cellule nk o cellule t e loro usi
WO2019084552A1 (en) 2017-10-27 2019-05-02 The Regents Of The University Of California TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS
US11225670B2 (en) 2017-10-30 2022-01-18 Corteva Agriscience Llc Plant promoter for transgene expression
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
BR112020008568A2 (pt) 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
WO2019094928A1 (en) 2017-11-10 2019-05-16 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
US12221720B2 (en) 2017-11-13 2025-02-11 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
CN111601883B (zh) 2017-11-17 2024-06-21 艾欧凡斯生物治疗公司 由细针抽吸物和小活检物扩增til
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3728587A4 (de) 2017-12-18 2022-01-26 Syngenta Participations Ag Stellen zur gezielten insertion im maisgenom
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
KR20250048610A (ko) 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
CN111819285B (zh) 2018-01-09 2024-08-09 希博斯美国有限公司 防碎基因和突变
EP3737226A1 (de) 2018-01-12 2020-11-18 Two Blades Foundation Stammrostresistenzgene und verfahren zur verwendung
JP7391854B2 (ja) 2018-01-17 2023-12-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ－ｐｋ阻害剤
AU2019209292B2 (en) 2018-01-17 2023-10-05 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
BR112020014140A2 (pt) 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated inibidores de dna-pk
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
US11926835B1 (en) 2018-01-29 2024-03-12 Inari Agriculture Technology, Inc. Methods for efficient tomato genome editing
CN111954540A (zh) 2018-02-08 2020-11-17 桑格摩生物治疗股份有限公司 工程化靶标特异性核酸酶
US20210017509A1 (en) 2018-03-23 2021-01-21 The Trustees Of Columbia University In The City Of New York Gene Editing for Autosomal Dominant Diseases
WO2019191495A1 (en) 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
AU2019247403B2 (en) 2018-04-04 2025-04-10 Cibus Europe, B.V. FAD2 genes and mutations
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
EP3775238A1 (de) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Verfahren zur herstellung von zellen, die einen rekombinanten rezeptor exprimieren, und verwandte zusammensetzungen
CN116536272A (zh) 2018-04-06 2023-08-04 儿童医疗中心有限公司 用于体细胞重新编程和调整印记的组合物和方法
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
CN110396132B (zh) * 2018-04-20 2022-12-02 上海科技大学 具有细胞穿膜性的锌指蛋白-超氧化物歧化酶融合蛋白质
DK3560330T3 (da) 2018-04-24 2022-07-11 Kws Saat Se & Co Kgaa Planter med forbedret fordøjelighed og markørhaplotyper
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
EP3784254A1 (de) 2018-04-27 2021-03-03 Iovance Biotherapeutics, Inc. Geschlossenes verfahren zur expansion und geneditierung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
KR20250133482A (ko) 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
EP3790629A1 (de) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Verfahren und zusammensetzungen zur behandlung von krebs
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3784776A4 (de) 2018-05-23 2022-01-26 National University of Singapore Blockade der cd2-oebrflächenexpression und expression chimärer antigenrezeptoren für die immuntherapie von t-zell-malignomen
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US11866719B1 (en) 2018-06-04 2024-01-09 Inari Agriculture Technology, Inc. Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
EP3802807B1 (de) 2018-06-05 2024-11-20 LifeEDIT Therapeutics, Inc. Rna-gesteuerte nukleasen, aktive fragmente und varianten davon und verwendungsverfahren
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
US11827892B2 (en) 2018-06-07 2023-11-28 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
CA3102975A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019246483A1 (en) 2018-06-21 2019-12-26 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
EP3820495A4 (de) 2018-07-09 2022-07-20 The Broad Institute Inc. Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
WO2020028617A1 (en) 2018-08-01 2020-02-06 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
CN112805379B (zh) 2018-08-03 2024-08-20 比姆医疗股份有限公司 多效应核碱基编辑器和使用其修饰核酸靶序列的方法
WO2020033601A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
US12421507B2 (en) 2018-08-20 2025-09-23 The Broad Institute, Inc. Methods and compositions for optochemical control of CRISPR-CAS9
EP3841204A4 (de) 2018-08-23 2022-05-18 Sangamo Therapeutics, Inc. Modifizierte zielspezifische basiseditoren
EP3844287B1 (de) 2018-08-31 2024-05-22 Yale University Zusammensetzungen und verfahren zur verbesserung der oligonukleotidbasierten geneditierung
WO2020047353A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
WO2020051283A1 (en) 2018-09-05 2020-03-12 The Regents Of The University Of California Generation of heritably gene-edited plants without tissue culture
US12398402B2 (en) 2018-09-12 2025-08-26 Fred Hutchinson Cancer Center Reducing CD33 expression to selectively protect therapeutic cells
AU2019344927A1 (en) 2018-09-18 2021-04-01 Sangamo Therapeutics, Inc. Programmed cell death 1 (PD1) specific nucleases
EP3852813A4 (de) 2018-09-18 2022-06-22 VNV Newco Inc. Lichtbogenbasierte kapside und deren verwendungen
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CN113226333A (zh) 2018-10-02 2021-08-06 桑格摩生物治疗股份有限公司 用于调控Tau蛋白的方法和组合物
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
EP3867375A1 (de) 2018-10-15 2021-08-25 Fondazione Telethon Genomeditierungsverfahren und konstrukte
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US12583816B2 (en) 2018-10-18 2026-03-24 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020088631A1 (en) 2018-11-01 2020-05-07 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
CR20210295A (es) 2018-11-05 2021-07-09 Iovance Biotherapeutics Inc Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202039829A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 改善之腫瘤反應性ｔ細胞的選擇
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
WO2020095248A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
US20220226375A1 (en) 2018-11-07 2022-07-21 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
WO2020095249A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
US12165743B2 (en) 2018-11-09 2024-12-10 The Broad Institute, Inc. Compressed sensing for screening and tissue imaging
US12402610B2 (en) 2018-11-09 2025-09-02 The Broad Institute, Inc. Methods and compositions for modulating innate lymphoid cell pathogenic effectors
WO2020102659A1 (en) 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
CA3120570A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
SG11202105480WA (en) 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
CA3121781A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
AU2019406778A1 (en) 2018-12-17 2021-07-22 Massachusetts Institute Of Technology Crispr-associated transposase systems and methods of use thereof
WO2020131547A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
CN113396326A (zh) 2018-12-19 2021-09-14 核酸有限责任公司 用于分子诊断的设备和方法
SG11202106977PA (en) 2018-12-27 2021-07-29 Lifeedit Therapeutics Inc Polypeptides useful for gene editing and methods of use
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
EP3908291A4 (de) 2019-01-07 2023-01-11 Dana-Farber Cancer Institute, Inc. Niedermolekulare degrader von fkbp12 über rekrutierung der von-hippel-lindau-e3-ubiquitin-ligase (vhl) und verwendung in dtag-systemen
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
US12156877B1 (en) 2019-01-15 2024-12-03 The Regents Of The University Of California Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
EP3921417A4 (de) 2019-02-04 2022-11-09 The General Hospital Corporation Varianten von adenin-dna-basen mit reduzierter off-target-rna-editierung
WO2020163017A1 (en) 2019-02-06 2020-08-13 Klogenix Llc Dna binding proteins and uses thereof
US11857641B2 (en) 2019-02-06 2024-01-02 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
CN111544585B (zh) 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
US20230053540A1 (en) 2019-02-19 2023-02-23 Massachusetts Institute Of Technology Treatment of liver injury
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
KR20210136050A (ko) 2019-03-01 2021-11-16 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
CN114174327A (zh) 2019-03-08 2022-03-11 黑曜石疗法公司 用于可调整调控的cd40l组合物和方法
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020186237A1 (en) 2019-03-13 2020-09-17 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
EP3937969A1 (de) 2019-03-14 2022-01-19 The Broad Institute, Inc. Zusammensetzungen und verfahren zur modulation der cgrp-signalisierung zur regulierung der angeborenen lymphoiden darmzellen
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
EP3942023A1 (de) 2019-03-18 2022-01-26 The Broad Institute, Inc. Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
EP3942043A2 (de) 2019-03-19 2022-01-26 The Broad Institute, Inc. Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US20200316116A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Method for the treatment of beta-thalassemia
CN113950526B (zh) 2019-04-09 2025-03-21 加利福尼亚大学董事会 通过靶向体内表观遗传阻遏实现的持久镇痛
US20230165976A1 (en) 2019-04-10 2023-06-01 University Of Utah Research Foundation Htra1 modulation for treatment of amd
US20220204975A1 (en) 2019-04-12 2022-06-30 President And Fellows Of Harvard College System for genome editing
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
PH12021552554A1 (en) 2019-04-23 2022-07-04 Sangamo Therapeutics Inc Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
US20220243287A1 (en) 2019-05-13 2022-08-04 KWS SAAT SE & Co. KGaA Drought tolerance in corn
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20220249701A1 (en) 2019-05-14 2022-08-11 The Broad Institute, Inc. Compositions and methods for targeting multinucleated cells
AR118995A1 (es) 2019-05-25 2021-11-17 Kws Saat Se & Co Kgaa Mejorador de la inducción de haploides
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
WO2020243485A1 (en) 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CA3138501A1 (en) 2019-06-13 2020-12-17 Thomas Charles PERTEL Anti-talen antibodies and uses thereof
CN120665955A (zh) 2019-06-25 2025-09-19 伊纳瑞农业技术有限公司 改善的同源依赖修复基因组编辑
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
KR20220026586A (ko) 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
BR112021026248A2 (pt) 2019-06-27 2022-03-03 Two Blades Found Molécula de ácido nucleico isolada que codifica uma proteína atrlp23 engenheirada, proteína atrlp23 engenheirada, cassete de expressão, vetor, célula hospedeira, planta ou célula vegetal, métodos para fazer uma proteína atrlp23 engenheirada, para fazer uma molécula de ácido nucleico que codifica uma proteína atrlp23 engenheirada e para intensificar a resistência de uma planta
WO2021011348A1 (en) 2019-07-12 2021-01-21 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
CA3146967A1 (en) 2019-07-17 2021-01-21 Fate Therapeutics, Inc. Immune effector cell engineering and use thereof
JP7708737B2 (ja) 2019-07-18 2025-07-15 ユニバーシティー オブ ロチェスター 細胞の細胞型選択的免疫保護
US11746354B2 (en) 2019-07-19 2023-09-05 Inari Agriculture Technology, Inc. Homology dependent repair genome editing
WO2021022043A2 (en) 2019-07-30 2021-02-04 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
EP3772542A1 (de) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifzierung der genetischen variation bei nutzpflanzen durch modulation des pachytän-checkpointproteins 2
EP4010474A1 (de) 2019-08-08 2022-06-15 The Broad Institute, Inc. Basiseditoren mit diversifiziertem zielbereich
WO2021030344A1 (en) 2019-08-12 2021-02-18 Lifeedit, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
US12485180B2 (en) 2019-08-30 2025-12-02 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
MX2022002763A (es) 2019-09-06 2022-04-06 Crispr Therapeutics Ag Linfocitos t modificados por ingenieria genetica que tienen persistencia mejorada en cultivo.
AU2020352552A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
CN114391040A (zh) 2019-09-23 2022-04-22 欧米茄治疗公司 用于调节载脂蛋白b(apob)基因表达的组合物和方法
US20230002459A1 (en) 2019-10-02 2023-01-05 Sangamo Therapeutics, Inc. Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021074367A1 (en) 2019-10-17 2021-04-22 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
US12385053B2 (en) 2019-10-22 2025-08-12 Inari Agriculture Technology, Inc. Genomic alteration of plant germline
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20230048224A1 (en) 2019-11-01 2023-02-16 Sangamo Therapeutics, Inc. Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
TW202132565A (zh) 2019-11-01 2021-09-01 美商聖加莫治療股份有限公司 Ｇｉｎ重組酶變異體
US20230086199A1 (en) 2019-11-26 2023-03-23 The Broad Institute, Inc. Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
US12241830B2 (en) 2019-12-06 2025-03-04 Broad Institute, Inc. Living biosensors
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
EP4074821A4 (de) 2019-12-13 2024-01-17 Chugai Seiyaku Kabushiki Kaisha System zum detektieren von extrazellulären purinergen rezeptor-liganden und nicht-menschliches tier, in das dieser ligand übertragen wurde
JP2023508731A (ja) 2019-12-30 2023-03-03 ライフエディット セラピューティクス，インコーポレイティド Ｒｎａ誘導ヌクレアーゼ、その活性断片および多様体、ならびに使用方法
MX2022008415A (es) 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
WO2021142835A1 (zh) 2020-01-19 2021-07-22 北京卡替医疗技术有限公司 一种提升免疫细胞功能的增强受体
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
EP4707398A2 (de) 2020-02-05 2026-03-11 The Broad Institute, Inc. Geneditierungsverfahren zur behandlung von spinaler muskelatrophie
EP4100519A2 (de) 2020-02-05 2022-12-14 The Broad Institute, Inc. Adeninbaseneditoren und verwendungen davon
EP4114937A4 (de) 2020-03-04 2024-09-04 Flagship Pioneering Innovations VI, LLC Verfahren und zusammensetzungen zur modulierung eines genoms
EP4114951A4 (de) 2020-03-05 2024-05-08 The Regents Of The University Of California Verfahren zur herstellung von pflanzen mit minimiertem biomassenebenprodukt und zugehörige pflanzen davon
EP4118230A4 (de) 2020-03-09 2024-04-24 Nuclein, LLC Vorrichtung und verfahren zur molekularen diagnose
WO2021183720A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
BR112022019060A2 (pt) 2020-03-25 2022-11-29 Sana Biotechnology Inc Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
AU2021248679A1 (en) 2020-04-02 2022-10-27 Takeda Pharmaceutical Company Limited ADAMTS13 variant, compositions, and uses thereof
TW202208626A (zh) 2020-04-24 2022-03-01 美商生命編輯公司 Rna引導核酸酶及其活性片段與變體，以及使用方法
WO2021222318A1 (en) 2020-04-28 2021-11-04 The Broad Institute, Inc. Targeted base editing of the ush2a gene
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4146797A1 (de) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Behandlung von neurodegenerativen erkrankungen
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
US12534744B2 (en) 2020-05-06 2026-01-27 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CA3173882A1 (en) 2020-05-11 2021-11-18 Alexandra Briner CRAWLEY Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021239986A1 (en) 2020-05-29 2021-12-02 KWS SAAT SE & Co. KGaA Plant haploid induction
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
EP4161552A1 (de) 2020-06-05 2023-04-12 The Broad Institute, Inc. Zusammensetzungen und verfahren zur behandlung von neoplasien
MX2022015863A (es) 2020-06-19 2023-03-23 Fate Therapeutics Inc Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia.
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
CA3173949A1 (en) 2020-07-15 2022-01-20 LifeEDIT Therapeutics, Inc. Uracil stabilizing proteins and active fragments and variants thereof and methods of use
JP7798855B2 (ja) 2020-07-16 2026-01-14 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に使用するためのカチオン性脂質
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
AU2021321586A1 (en) 2020-08-07 2023-03-16 Dana-Farber Cancer Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex
US20230304047A1 (en) 2020-08-11 2023-09-28 University Of Oslo Improved gene editing
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
EP4501951A3 (de) 2020-08-25 2025-04-30 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
IL301014A (en) 2020-08-31 2023-05-01 Univ Yale Compositions and methods for delivery of nucleic acids to cells
EP4211235A2 (de) 2020-09-11 2023-07-19 Lifeedit Therapeutics, Inc. Dna-modifizierende enzyme und aktive fragmente sowie varianten davon und verfahren zur verwendung
AU2021347907A1 (en) 2020-09-23 2023-04-20 Crispr Therapeutics Ag Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
KR20230074519A (ko) 2020-09-25 2023-05-30 상가모 테라퓨틱스, 인코포레이티드 핵염기 편집을 위한 아연 핑거 융합 단백질
EP4225330A1 (de) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
US20240000051A1 (en) 2020-11-16 2024-01-04 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
AU2021409729A1 (en) 2020-12-22 2023-07-13 Nchroma Bio, Inc. Compositions and methods for epigenetic editing
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
EP4274894A2 (de) 2021-01-11 2023-11-15 The Broad Institute, Inc. Prime-editor-varianten, konstrukte und verfahren zur verbesserung der prime-editierungseffizienz und -präzision
EP4277989A2 (de) 2021-01-12 2023-11-22 March Therapeutics, Inc. Kontextabhängige doppelsträngige dna-spezifische deaminasen und verwendungen davon
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
EP4284823A1 (de) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation der tgf-beta-signalisierung in genetisch modifizierten eukaryotischen zellen
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
KR20230147644A (ko) * 2021-02-04 2023-10-23 뉴욕 유니버시티 천연 기능을 징발하기 위한 내인성 전사 인자에 조작된 징크 핑거의 원활한 통합
JP2024506645A (ja) 2021-02-11 2024-02-14 コーニンクレッカ ネザーランド アカデミー ヴァン ウェテンシャッペン 転写調節遺伝子の編集による疾患の治癒
WO2022178307A1 (en) 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
EP4305153A1 (de) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetisch veränderte t-zellen mit ptpn2-knockout mit verbesserter funktionalität und antitumoraktivität
JP2024510505A (ja) 2021-03-19 2024-03-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
KR20230158573A (ko) 2021-03-22 2023-11-20 주노 쎄러퓨티크스 인코퍼레이티드 바이러스 벡터 입자의 효력을 평가하는 방법
CN117295817A (zh) 2021-03-22 2023-12-26 生命编辑制药股份有限公司 Dna修饰酶及其活性片段和变体以及使用方法
JP2024511414A (ja) 2021-03-23 2024-03-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のｃｉｓｈ遺伝子編集及び免疫療法におけるその使用
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3214045A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
KR20240037185A (ko) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
EP4334438A1 (de) 2021-05-05 2024-03-13 Fujifilm Cellular Dynamics, Inc. Verfahren und zusammensetzungen für mikroglia aus ipsc
EP4336997A1 (de) 2021-05-11 2024-03-20 Two Blades Foundation Verfahren zur herstellung einer bibliothek von pflanzenkrankheitsresistenzgenen zur funktionellen prüfung auf krankheitsresistenz
CA3217426A1 (en) 2021-05-14 2022-11-17 Alvaro GODINEZ Multiplexed unbiased nucleic acid amplification method
EP4341390A4 (de) 2021-05-14 2025-02-19 Becton, Dickinson and Company Verfahren zur herstellung von bibliotheken zur nukleinsäuresequenzierung
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
JP2024519895A (ja) 2021-05-18 2024-05-21 賽斯尓▲チン▼生物技術（上海）有限公司 細胞を修飾する方法
US20250057952A1 (en) 2021-05-21 2025-02-20 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
JP2024521817A (ja) 2021-05-27 2024-06-04 サンバイオ，インコーポレイテッド 小体積脳卒中のための細胞療法及び治療方法
BR112023024434A2 (pt) 2021-05-27 2024-02-20 Sana Biotechnology Inc Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
WO2022261509A1 (en) 2021-06-11 2022-12-15 The Broad Institute, Inc. Improved cytosine to guanine base editors
AU2022290278A1 (en) 2021-06-11 2024-01-04 LifeEDIT Therapeutics, Inc. Rna polymerase iii promoters and methods of use
US12577529B2 (en) 2021-06-17 2026-03-17 Quiver Holdings Inc. Methods for producing neural cells
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
EP4370544A2 (de) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Veränderte expression von y-chromosom-gebundenen antigenen in hypoimmunogenen zellen
US20240336663A1 (en) * 2021-07-16 2024-10-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeting myd88 gene in vitro and in vivo
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
EP4377459A2 (de) 2021-07-30 2024-06-05 Tune Therapeutics, Inc. Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
CA3221517A1 (en) 2021-07-30 2023-02-02 Monika KLOIBER-MAITZ Plants with improved digestibility and marker haplotypes
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
JP2024530487A (ja) 2021-08-06 2024-08-21 ザ ブロード インスティテュート，インコーポレーテッド 改善されたプライムエディターおよび使用方法
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024531234A (ja) 2021-08-11 2024-08-29 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法のための遺伝子改変された初代細胞
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023035011A1 (en) 2021-09-03 2023-03-09 North Carolina State University Compositions and methods for conferring resistance to geminivirus
CA3230629A1 (en) 2021-09-08 2023-03-16 Beam Therapeutics Inc. Viral guide rna delivery
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
KR20240055838A (ko) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 유도된 만능 줄기 세포 유래된 세포의 조성물 및 이의 사용 방법
US20230128917A1 (en) 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
KR20240095525A (ko) 2021-09-21 2024-06-25 스크라이브 테라퓨틱스 인크. 조작된 casx 억제 시스템
WO2023055893A1 (en) * 2021-09-30 2023-04-06 Peter Biotherapeutics, Inc. Gene regulation
WO2023056269A1 (en) 2021-09-30 2023-04-06 Two Blades Foundation Plant disease resistance genes against stem rust and methods of use
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
WO2023069881A1 (en) 2021-10-20 2023-04-27 University Of Rochester Treatment with genetically modified cells, and genetically modified cells per se, with increased competitive advantage and/or decreased competitive disadvantage
AU2022371442A1 (en) 2021-10-21 2024-04-18 Vertex Pharmaceuticals Incorporated Hypoimmune cells
US20250313861A1 (en) 2021-10-22 2025-10-09 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
US20240409934A1 (en) 2021-10-25 2024-12-12 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3235390A1 (en) 2021-10-29 2023-05-04 Deepika Rajesh Dopaminergic neurons comprising mutations and methods of use thereof
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
CN119120424A (zh) 2021-11-02 2024-12-13 辉大(上海)生物科技有限公司 一种CRISPR-Cas12i系统
EP4426832A1 (de) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Genaue genomeditierung mit retrons
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
US20250108121A1 (en) 2021-11-09 2025-04-03 Amgen Inc. Method for producing an antibody peptide conjugate
US20240408236A1 (en) 2021-11-26 2024-12-12 Epigenic Therapeutics, Inc. Method of modulating pcsk9 and uses thereof
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
CA3239381A1 (en) 2021-12-03 2023-06-08 David R. Liu Compositions and methods for efficient in vivo delivery
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4452335A1 (de) 2021-12-22 2024-10-30 Tome Biosciences, Inc. Gemeinsame freisetzung eines geneditorkonstrukts und eines spendertemplates
WO2023119201A2 (en) 2021-12-22 2023-06-29 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
US20250361528A1 (en) 2021-12-22 2025-11-27 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CN119317713A (zh) 2022-01-24 2025-01-14 生命编辑制药股份有限公司 Rna引导核酸酶、其活性片段与变体，及使用方法
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
EP4472648A1 (de) 2022-02-01 2024-12-11 University of Rochester Verfahren zur erzeugung einer population von neuronen aus menschlichen glialvorläuferzellen und genetische konstrukte zur durchführung solcher verfahren
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
JP2025508720A (ja) 2022-02-17 2025-04-10 サナ バイオテクノロジー，インコーポレイテッド 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照
TW202340457A (zh) 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
US12037616B2 (en) 2022-03-01 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
KR20240151871A (ko) 2022-03-04 2024-10-18 시그마-알드리치 컴퍼니., 엘엘씨 아스파라긴 생합성 경로를 통한 대사 선택
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
TW202403046A (zh) 2022-03-21 2024-01-16 瑞士商Ｃｒｉｓｐｒ治療公司 用於治療脂蛋白相關的疾病之方法及組成物
TW202346575A (zh) 2022-03-23 2023-12-01 瑞士商Ｃｒｉｓｐｒ治療公司 具有ｒｅｇｎａｓｅ－１及／或ｔｇｆｂｒｉｉ破壞的抗ｃｄ８３ ｃａｒ－ｔ細胞
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
US20230302423A1 (en) 2022-03-28 2023-09-28 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
CA3255225A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California COMPOSITIONS AND METHODS OF GENETIC COMPLEMENTATION
EP4504925A1 (de) 2022-04-04 2025-02-12 The Broad Institute, Inc. Cas9-varianten mit nichtkanonischen pam-spezifitäten und verwendungen davon
CA3247638A1 (en) 2022-04-06 2023-10-12 Maria Fardis TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
JP7707304B2 (ja) 2022-04-08 2025-07-14 フェイト セラピューティクス，インコーポレイティド 腫瘍標的化のためのキメラ抗原受容体
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
CN120456933A (zh) 2022-04-28 2025-08-08 布罗德研究所股份有限公司 编码碱基编辑器的aav载体及其用途
WO2023215711A1 (en) 2022-05-01 2023-11-09 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of pcsk9 expression
CN119136844A (zh) 2022-05-02 2024-12-13 泰莱托恩基金会第三部门组织 用于基因编辑的同源非依赖性靶向整合
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
EP4522210A1 (de) 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvovirus mit modifiziertem genom zur gentherapie
EP4522203A1 (de) 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvovirus mit modifiziertem kapsid zur gentherapie
WO2023220035A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus compositions and methods for gene therapy
US20250281537A1 (en) 2022-05-10 2025-09-11 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
EP4278891A1 (de) 2022-05-20 2023-11-22 KWS SAAT SE & Co. KGaA Kohlhernienresistenz und marker in brassica
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
CA3255335A1 (en) 2022-05-27 2023-11-30 President And Fellows Of Harvard College IMPROVED MITOCHONDRIAL BASIS EDITORS AND MITOCHONDRIAL DNA EDITING METHODS
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
CA3257650A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
EP4540387A2 (de) 2022-06-17 2025-04-23 CRISPR Therapeutics AG Auf lipidnanopartikeln (lnps) basierende okulare freisetzung
US20250381304A1 (en) 2022-06-21 2025-12-18 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
EP4544059A1 (de) 2022-06-23 2025-04-30 Chroma Medicine, Inc. Zusammensetzungen und verfahren zur epigenetischen regulierung der b2m-expression
WO2023250512A1 (en) 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of ciita expression
JP2025524455A (ja) 2022-06-23 2025-07-30 エヌクロマ・バイオ，インコーポレーテッド Ｔｒａｃ発現のエピジェネティック調節のための組成物及び方法
KR20250044484A (ko) 2022-06-24 2025-03-31 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
GB2621813A (en) 2022-06-30 2024-02-28 Univ Newcastle Preventing disease recurrence in Mitochondrial replacement therapy
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
EP4554967A2 (de) 2022-07-12 2025-05-21 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur gezielten transkriptionsaktivierung
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
AU2023311477A1 (en) 2022-07-22 2025-01-30 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024023067A1 (en) 2022-07-25 2024-02-01 Koninklijke Nederlandse Akademie Van Wetenschappen Curing disease by transcription regulatory gene editing
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
MA71732A (fr) 2022-08-12 2025-05-30 Life Edit Therapeutics, Inc. Nucléases guidées par arn et fragments actifs, variants associés et procédés d'utilisation
EP4573191A1 (de) 2022-08-16 2025-06-25 The Broad Institute, Inc. Entwickelte cytosin-deaminasen und verfahren zur dna-editierung damit
WO2024038168A1 (en) 2022-08-19 2024-02-22 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such
CN120435557A (zh) 2022-08-19 2025-08-05 图恩疗法股份有限公司 通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
EP4577650A1 (de) 2022-08-25 2025-07-02 Life Edit Therapeutics, Inc. Chemische modifikation von guide-rnas mit verriegelter nukleinsäure zur rna-geführten nukleasevermittelten geneditierung
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024042168A1 (en) 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2024042165A2 (en) 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
US20250386788A1 (en) 2022-08-26 2025-12-25 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding
CN117624375A (zh) 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
IL319704A (en) 2022-09-23 2025-05-01 Nchroma Bio Inc Compositions and methods for epigenetic regulation of HBV gene expression
JP2025536205A (ja) 2022-09-30 2025-11-05 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー グリシン－ギ酸生合成経路による代謝選択
US20260085327A1 (en) 2022-09-30 2026-03-26 Sigma-Aldrich Co. Llc. Metabolic selection via the serine biosynthesis pathway
CA3265701A1 (en) 2022-10-11 2024-04-18 KWS SAAT SE & Co. KGaA VIRUS AND INSECT RESISTANCE AND MARKERS IN BARLEY
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
WO2024081879A1 (en) 2022-10-14 2024-04-18 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of cd247 expression
JP2025536578A (ja) 2022-11-03 2025-11-07 セレクティス ソシエテ アノニム Ｔ細胞媒介免疫療法の有効性及び安全性の増進
EP4612277A1 (de) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Verfahren zur expansion von tumorinfiltrierenden lymphozyten (til) im zusammenhang mit cd39/cd103-auswahl
AU2023374241A1 (en) 2022-11-04 2025-06-12 Life Edit Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
CN120239706A (zh) 2022-11-07 2025-07-01 先正达农作物保护股份公司 改变大豆植物开花时间和/或成熟的基因及其用途
EP4615960A1 (de) 2022-11-09 2025-09-17 C3S2 GmbH Verfahren zur herstellung von manipulierten immunzellen
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
AU2023375625A1 (en) 2022-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
KR20250122544A (ko) 2022-11-21 2025-08-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
AU2023406926A1 (en) 2022-12-01 2025-06-26 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
JP2026504733A (ja) 2022-12-16 2026-02-09 ライフ エディット セラピューティクス，インコーポレイティド Ｔｒａｃ遺伝子を標的とするガイドｒｎａおよび使用方法
US20240269189A1 (en) 2022-12-19 2024-08-15 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
TW202440931A (zh) 2022-12-23 2024-10-16 大陸商益杰立科（上海）生物科技有限公司 融合物及其用途
AU2023412431A1 (en) 2022-12-23 2025-08-07 Epigenic Therapeutics Pte. Ltd. Complex and use thereof
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
EP4652271A1 (de) 2023-01-18 2025-11-26 The Broad Institute, Inc. Baseneditierungsvermitteltes durchlesen von codons mit vorzeitiger terminierung (bert)
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
EP4658786A2 (de) 2023-02-03 2025-12-10 The Broad Institute Inc. Geneditierungsverfahren, systeme und zusammensetzungen zur behandlung von spinaler muskelatrophie
CN120712355A (zh) 2023-02-15 2025-09-26 阿伯生物技术公司 用于抑制抑微管装配蛋白2（stmn2）转录物中的异常剪接的基因编辑方法
WO2024187174A2 (en) 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
US12383615B2 (en) 2023-03-23 2025-08-12 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
WO2024211287A1 (en) 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
TW202507006A (zh) 2023-04-12 2025-02-16 美商生命編輯治療學公司 藉由編輯突變亨廷頓基因治療亨廷頓氏病之組合物及方法
IT202300007968A1 (it) 2023-04-21 2024-10-21 Fond Telethon Ets Metodi di editing genomico e costrutti
TW202444898A (zh) 2023-04-21 2024-11-16 美商凱特製藥公司 免疫排斥之風險降低的同種異體治療性細胞
CN121443140A (zh) 2023-04-21 2026-01-30 非营利性组织佛兰芒综合大学生物技术研究所 用于作物产量提升的等位基因组合
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2024235991A1 (en) 2023-05-15 2024-11-21 UCB Biopharma SRL Rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
IL324634A (en) 2023-05-15 2026-01-01 Nchroma Bio Inc Compositions and methods for epigenetic regulation of hbv gene expression
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
CN121772943A (zh) 2023-05-16 2026-03-31 旗舰实验室114公司 调节靶基因的甲基化的方法和组合物
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2025003358A2 (en) 2023-06-29 2025-01-02 UCB Biopharma SRL Novel nucleic acid targeting systems comprising rna-guided nucleases
TW202515898A (zh) 2023-06-30 2025-04-16 日商武田藥品工業股份有限公司 Ｈｔｔ抑制物及其用途
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
EP4743481A1 (de) 2023-07-14 2026-05-20 Two Blades Found Verfahren zur verbesserung der thermostabilität von pflanzenimmunrezeptoren
EP4743480A1 (de) 2023-07-15 2026-05-20 Two Blades Found Breitband-polrovirus-resistenzgen
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
US20250027087A1 (en) 2023-07-21 2025-01-23 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025022367A2 (en) 2023-07-27 2025-01-30 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
CN121620588A (zh) 2023-07-31 2026-03-06 西格马-奥尔德里奇有限责任公司 经由丙氨酸生物合成途径的代谢选择
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025059215A1 (en) 2023-09-12 2025-03-20 Aadigen, Llc Methods and compositions for treating or preventing cancer
WO2025064469A1 (en) 2023-09-18 2025-03-27 Omega Therapeutics, Inc. Methods for assessing dosage for epigenetic modifying agents
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
GB202314578D0 (en) 2023-09-22 2023-11-08 Univ Manchester Methods of producing homoplasmic modified plants or parts thereof
WO2025083619A1 (en) 2023-10-18 2025-04-24 Life Edit Therapeutics, Inc. Rna-guided nucleases and acive fragments and variants thereof and methods of use
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025160155A1 (en) 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases
WO2025168705A1 (en) 2024-02-08 2025-08-14 Vib Vzw Means and methods for the production of saponins with endosomal escape-enhancing properties
TW202546224A (zh) 2024-02-12 2025-12-01 美商生命編輯治療學公司 新穎的ｒｎａ引導之核酸酶及用於聚合酶編輯之蛋白質
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2025194124A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
EP4677108A1 (de) 2024-04-22 2026-01-14 Basecamp Research Ltd Verfahren und zusammensetzungen zur erkennung von off-target-editierung
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2025224715A1 (en) 2024-04-26 2025-10-30 King Abdullah Univeristy Of Science And Technology Methods for improving precise genome modification and reducing unwanted mutations by crispr-cas editing
WO2025235563A1 (en) 2024-05-07 2025-11-13 Omega Therapeutics, Inc. Epigenetic modulation for upregulation of genes
TW202605143A (zh) 2024-05-10 2026-02-01 美商奇諾治療有限公司 表現cd19嵌合抗原受體(car)之基因工程化t細胞及其用於同種異體細胞療法之用途
US20250381230A1 (en) 2024-06-14 2025-12-18 SanBio Co. Ltd. Methods and compositions for treatment of neurodegenerative disorders and reducing tau protein aggregates
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026003754A1 (en) 2024-06-25 2026-01-02 Life Edit Therapeutics, Inc. Novel reverse transcriptases and uses thereof
WO2026006832A1 (en) 2024-06-28 2026-01-02 University Of Connecticut Gene modulation for treating cancer
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026030277A1 (en) 2024-08-01 2026-02-05 Amgen Inc. Method for reducing protease activities
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
WO2026072421A2 (en) 2024-09-27 2026-04-02 The Broad Institute, Inc. Base editing methods and compositions for editing prnp in the treatment of prion disease
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair
WO2026096383A1 (en) 2024-10-28 2026-05-07 The Broad Institute, Inc. Compositions and methods for inducing phagocytosis

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US553409A (en) * 1896-01-21 Globe and method of making same
DE3410650A1 (de) 1984-03-23 1985-10-03 Kernforschungsanlage Jülich GmbH, 5170 Jülich Mit mikroorganismen bewachsene poroese anorganische traeger, verfahren zur immobilisierung von mikroorganismen und dafuer geeignete traegerkoerper
US5455170A (en) * 1986-08-22 1995-10-03 Hoffmann-La Roche Inc. Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05
US5317090A (en) 1987-12-16 1994-05-31 Institut Pasteur Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human hepatocellular carcinoma, and which is a retinoic acid receptor
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5340739A (en) 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5602009A (en) 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
JPH04504654A (ja) 1988-12-23 1992-08-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ レセプターの転写抑制活性組成物および方法
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US4990607A (en) 1989-03-14 1991-02-05 The Rockefeller University Alteration of gene expression in plants
US5597693A (en) 1989-03-17 1997-01-28 The Salk Institute For Biological Studies Hormone response element compositions and assay
WO1991007509A1 (en) 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
WO1992002536A1 (en) 1990-08-02 1992-02-20 The Regents Of The University Of Colorado Systematic polypeptide evolution by reverse translation
CA2090407A1 (en) 1990-09-21 1992-03-22 Ronald M. Evans Functional antagonism between proto-oncoprotein c-jun and hormone receptors
US5348864A (en) 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5324818A (en) 1991-08-21 1994-06-28 The Regents Of The University Of Michigan Proteins useful in the regulation of κB-containing genes
US5243041A (en) 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5302519A (en) 1991-09-09 1994-04-12 Fred Hutchinson Cancer Research Center Method of producing a Mad polypeptide
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5916794A (en) 1992-04-03 1999-06-29 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5324638A (en) 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
GB9226065D0 (en) * 1992-12-14 1993-02-10 Ici Plc Peptides
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0770129B1 (de) 1994-01-18 2005-11-23 The Scripps Research Institute Derivate von zinkfingerproteinen und methoden
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1996006110A1 (en) 1994-08-18 1996-02-29 Gilman, Michael, Z. Composite dna-binding proteins and materials and methods relating thereto
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
CA2196419C (en) * 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
DE4435919C1 (de) 1994-10-07 1995-12-07 Deutsches Krebsforsch Zinkfinger-DNA, -Protein und ihre Verwendung
US5871902A (en) 1994-12-09 1999-02-16 The Gene Pool, Inc. Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
ATE544776T1 (de) 1994-12-29 2012-02-15 Massachusetts Inst Technology Chimäre dna-bindeproteine
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5935811A (en) 1995-03-03 1999-08-10 California Institute Of Technology Neuron-restrictive silencer factor nucleic acids
US6090783A (en) * 1995-03-24 2000-07-18 Shionogi & Co., Ltd. DNA molecule relating to suppression of gene expression and novel protein
AU5445296A (en) 1995-04-12 1996-10-30 Cheng Cheng Methods for preparing dna-binding proteins
DE69711599T2 (de) 1996-01-11 2002-10-31 Honeywell International Inc., Morristown Elektrischer drossel mit verteilte spalt
US6153380A (en) 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
GB9606166D0 (en) 1996-03-23 1996-05-29 Hienemann Vivienne S Greetings device
US6265196B1 (en) 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US6388055B1 (en) * 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
US5939538A (en) * 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
DE19718249A1 (de) 1997-04-30 1998-11-05 Basf Ag Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US7119250B2 (en) * 1997-06-03 2006-10-10 The University Of Chicago Plant centromere compositions
US6383746B1 (en) * 1997-10-23 2002-05-07 The United States Of America As Represented By The Department Of Health And Human Services Functional promoter for CCR5
GB9724829D0 (en) 1997-11-21 1998-01-21 Muller Rolf Transcription factor
EP1046034A1 (de) 1998-01-09 2000-10-25 Cubist Pharmaceuticals, Inc. Verfahren zur identifizierung von ziel und test kombinationen
CA2318402A1 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
DE69933856D1 (de) 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6205404B1 (en) 1998-02-20 2001-03-20 George S. Michaels DNA-binding proteins of the zinc-finger class
AU746454B2 (en) 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6100087A (en) * 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
DE69932813D1 (de) 1998-03-17 2006-09-28 Gendaq Ltd Nukleinsäurebindungsproteine
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2001004296A1 (en) 1999-07-12 2001-01-18 Mcgill University Rbp1 polypeptides and uses thereof
US20020164575A1 (en) 1999-09-14 2002-11-07 Sangamo Biosciences, Inc., A Delaware Corporation Gene identification
CN1482856A (zh) * 2000-11-09 2004-03-17 ����Ƽ���ҵ�о���֯ 降低了ssii活性的大麦和降低了支链淀粉含量的淀粉和淀粉制品
JP4309133B2 (ja) 2001-02-21 2009-08-05 ノバルティス アクチエンゲゼルシャフト ヌクレオチド配列ａｎｎについての亜鉛フィンガー結合ドメイン
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn

Also Published As

Publication number Publication date
US6607882B1 (en) 2003-08-19
US20020160940A1 (en) 2002-10-31
US20030087817A1 (en) 2003-05-08
US20120294838A1 (en) 2012-11-22
GB2348424B (en) 2001-03-14
US7163824B2 (en) 2007-01-16
US9491934B2 (en) 2016-11-15
DK1061805T3 (da) 2006-01-09
DE60022705T2 (de) 2006-06-14
US20060281704A1 (en) 2006-12-14
CA2323086A1 (en) 2000-07-20
DE20023745U1 (de) 2006-02-23
US7220719B2 (en) 2007-05-22
US6534261B1 (en) 2003-03-18
US6933113B2 (en) 2005-08-23
GB0000650D0 (en) 2000-03-01
US6824978B1 (en) 2004-11-30
EP1061805A1 (de) 2000-12-27
DE60022705D1 (de) 2005-10-27
CA2323086C (en) 2008-09-09
AU745844B2 (en) 2002-04-11
US20050130304A1 (en) 2005-06-16
US8268618B2 (en) 2012-09-18
US6979539B2 (en) 2005-12-27
DE60022705T8 (de) 2006-09-14
US20040204345A1 (en) 2004-10-14
EP1061805A4 (de) 2001-08-29
US20170251645A1 (en) 2017-09-07
ES2250103T3 (es) 2006-04-16
AU2847000A (en) 2000-08-01
WO2000041566A1 (en) 2000-07-20
US20050215502A1 (en) 2005-09-29
US20100261271A1 (en) 2010-10-14
JP5490971B2 (ja) 2014-05-14
JP2011207893A (ja) 2011-10-20
JP2001231583A (ja) 2001-08-28
GB2348424A (en) 2000-10-04
US20110247087A1 (en) 2011-10-06
US20100279406A1 (en) 2010-11-04
US20060276427A1 (en) 2006-12-07
US20140325691A1 (en) 2014-10-30
JP2002534104A (ja) 2002-10-15
EP1061805B1 (de) 2005-09-21
US7985887B2 (en) 2011-07-26
US20060078878A1 (en) 2006-04-13
WO2000041566A9 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
DE60022705D1 (de) Regulierung der endogenen genexpression in zellen unter verwendung von zinkfingerproteinen
CA2208013A1 (en) Recombinant dna molecules and expression vectors for erythropoietin
AR016537A1 (es) Una celula humana para la fabricacion de eritropoyetina por activacion genica endogena, un procedimiento para la fabricacion de la misma y una construccionde adn a ser usada en el mismo, un procedimiento para la fabricacion de epo humana, epo humana aislada obtenida por el mismo y un preparado farma
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE297987T1 (de) Bedingte immortalisierung von zellen
ATE218163T1 (de) Von pflanzen abgeleitetes enzym und dna-sequenzen und ihre verwendung
DE3486053D1 (de) Regulierung von gen-expression durch translationshemmung unter verwendung von m-rns hinderndem komplementaer-rns.
CY1105933T1 (el) Μονομepης πρωτεϊνη με μορφογενετικη δραστικοτητα οστου και μηχανικος παραγοντας πepιεχων την ιδια για προληψη και θepαπεια νοσων χονδρου και οστου
DE69840413D1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
EP1702071A4 (de) Transaktivierungssystem für säugerzellen
DE69930660D1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
FR2716205B1 (fr) Récepteur galanine, acides nucléiques, cellules transformées et utilisations.
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
AU5520390A (en) Dna coding for protein capable of combining with enhancer of alpha-fetoprotein gene
WO2003054172A3 (en) Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
EP0336383A3 (de) Menschliches rekombinantes Lymphotoxin
DK0733370T3 (da) Anvendelse af en genpromotorsekvens til behandling af rheumatiske sygdomme
DK1082408T3 (da) I IRAK-genet modificerede transgene mus
ES2136199T3 (es) Expresion multicistronica de genes recombinantes en celulas bacterianas.
Zhu et al. IVF bovine oocyte classification and selection
Yang et al. Biological nanopore control of synthesis: Single-molecule reaction and characterization
Comerci et al. A novel electrical device demonstrates localized stimulation triggers cell-type-specific proliferation in biofilms
Savinov et al. Mapping functional regions of essential bacterial proteins with dominant-negative protein fragments
MY136860A (en) Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1061805

Country of ref document: EP